Market
Significant safety concerns for veligrotug by end of 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Viridian Therapeutics press releases or clinical study reports
Story
Viridian Therapeutics' Veligrotug Shows Strong Efficacy in Phase 3 Trial for Thyroid Eye Disease
Dec 16, 2024, 12:26 PM
Viridian Therapeutics Inc. announced positive topline results from its Phase 3 THRIVE-2 clinical trial evaluating veligrotug, an intravenously administered anti-IGF-1R antibody, for the treatment of chronic thyroid eye disease (TED). The trial met all primary and secondary endpoints, showing statistically significant improvements in proptosis, diplopia, and Clinical Activity Scores (CAS) after only five infusions. The study involved 188 patients, with veligrotug demonstrating a 56% proptosis responder rate (PRR) compared to 8% for placebo, and a 56% diplopia response rate against 25% for placebo. The drug was generally well-tolerated, with a 9.6% placebo-adjusted rate of hearing impairment. Viridian is preparing for a Biologics License Application (BLA) submission in the second half of 2025, aiming to offer a differentiated product profile for TED patients. Additionally, the company is advancing its subcutaneous VRDN-003 program, with topline data expected in the first half of 2026.
View original story
Similar markets
Design flaws • 25%
Poor slope preparation • 25%
Weather conditions • 25%
Other • 25%
Moderate safety improvements recommended • 25%
Other • 25%
Major safety overhaul required • 25%
No significant issues found • 25%
Increased concern • 25%
Uncertain • 25%
Decreased concern • 25%
No significant change • 25%
Improved Fire Safety • 25%
Visitor Capacity Control • 25%
Enhanced Security Checks • 25%
Elevator System Upgrades • 25%
Emergency response • 25%
Pilot training • 25%
Aircraft maintenance • 25%
Air traffic control • 25%
Yes • 50%
No • 50%
Other • 25%
Technical issues • 25%
Security threat • 25%
Natural disaster • 25%
Structural integrity • 25%
Other • 25%
Visitor safety protocols • 25%
Fire prevention • 25%